The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

Clinical and Experimental Dermatology

Volume 33, Issue 6

Dermatological high‐dose‐rate brachytherapy for the treatment of basal and squamous cell carcinoma

A. F. Sedda

Physical Technologies and New Materials (FIM), Italian Agency for New Technologies, Energy and Environment (ENEA) Casaccia, Rome, Italy

Search for more papers by this author
G. Rossi

Physical Technologies and New Materials (FIM), Italian Agency for New Technologies, Energy and Environment (ENEA) Casaccia, Rome, Italy

Search for more papers by this author
C. Cipriani

Nuclear Medicine Department, S. Eugenio Hospital, Rome, Italy

Search for more papers by this author
A. M. Carrozzo

Dermatology Department, Tor Vergata University, Rome, Italy

Search for more papers by this author
P. Donati

S. Gallicano Hospital, IFO, Rome, Italy

Search for more papers by this author
First published: 06 October 2008
https://doi.org/10.1111/j.1365-2230.2008.02852.x
Cited by: 14
Dr Antioco Franco Sedda, FIM, ENEA‐Casaccia s.p. Anguillarese 301, 00123 Rome, Italy.
E‐mail: antioco.sedda@casaccia.enea.it

Conflict of interest: none declared.

Summary

Background. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most common cancers in humans. Various therapies are currently being used to treat these tumours including surgery, topical treatments and radiotherapy. We describe a new treatment for BCC and SCC. This consists of superficial radiotherapy, using synthetic resin containing a radioactive β‐emitting isotope. The resin is applied to the lesion to perform a selective β‐irradiation brachytherapy treatment.

Methods. In total, 53 patients with histologically confirmed diagnosis of BCC and of SCC were enrolled for the treatment.

Results. In all treated cases, an apparent clinical remission occurred in approximately 3 months, and complete healing was obtained in 100% of the treated patients; in 82% of the cases, this occurred after a single application. No disfiguring scars or any side‐effects were seen. After a follow‐up of 20–72 months (mean 51 months), no clinical relapses were observed in the treated patients. Histological examination confirmed complete tumour regression.

Conclusion. The results indicated that brachytherapy is an effective treatment for BCC and SCC.

Number of times cited: 14

  • Dakshika A Gunaratne and Michael J Veness, Efficacy of hypofractionated radiotherapy in patients with non‐melanoma skin cancer: Results of a systematic review, Journal of Medical Imaging and Radiation Oncology, 62, 3, (401-411), (2018).
    Wiley Online Library
  • S. Liverani, S. Vichi, F. Zagni, S. Riga, G. M. Lima, P. Castellucci, T. Wendler, M. Olmeda, M. Marengo and D. Mostacci, Determination of the activity meter calibration factor for Rhenium-188, Radiation Effects and Defects in Solids, 10.1080/10420150.2018.1528601, 173, 9-10, (758-762), (2018).
    Crossref
  • Anna Likhacheva, Skin Brachytherapy, Handbook of Image-Guided Brachytherapy, 10.1007/978-3-319-44827-5_15, (457-480), (2017).
    Crossref
  • Magali Fort, Saada Guet, Laurianne Colson-Durand, Claire Auzolle and Yazid Belkacemi, Role of radiation therapy in non-melanoma cancers, lymphomas and sarcomas of the skin: Systematic review and best practice in 2016, Critical Reviews in Oncology/Hematology, 99, (200), (2016).
    Crossref
  • Zoubir Ouhib, Michael Kasper, Jose Perez Calatayud, Silvia Rodriguez, Ajay Bhatnagar, Sujatha Pai and John Strasswimmer, Aspects of dosimetry and clinical practice of skin brachytherapy: The American Brachytherapy Society working group report, Brachytherapy, 14, 6, (840), (2015).
    Crossref
  • H.-J. Biersack, F. Stelzner and F. F. Knapp, Discovery of rhenium and masurium (technetium) by Ida Noddack-Tacke and Walter Noddack, Nuklearmedizin, 54, 6, (N50), (2015).
    Crossref
  • Justin M. Haseltine, A. Gabriella Wernicke, Silvia C. Formenti and Bhupesh Parashar, Treatment of Non-Melanomatous Skin Cancer with Radiotherapy, Current Dermatology Reports, 10.1007/s13671-015-0117-2, 4, 4, (187-194), (2015).
    Crossref
  • Bernardo Hontanilla, Shan‐Shan Qiu and Diego Marré, Effect of postoperative brachytherapy and external beam radiotherapy on functional outcomes of immediate facial nerve repair after radical parotidectomy, Head & Neck, 36, 1, (113-119), (2013).
    Wiley Online Library
  • Sanjay Kumar Saxena, Usha Pandey, Yogendra Kumar, Rubel Chakravarty, Haladhar Dev Sarma and Ashutosh Dash, On the Application of Nafion Membrane for the Preparation of90Y Skin Patches, Quality Control, and Biological Evaluation for Treatment of Superficial Tumors, Cancer Biotherapy & Radiopharmaceuticals, 29, 5, (200), (2014).
    Crossref
  • Pilar de la Puente and Abdel Kareem Azab, Delivery systems for brachytherapy, Journal of Controlled Release, 10.1016/j.jconrel.2014.06.057, 192, (19-28), (2014).
    Crossref
  • Ruth Gauden, Martin Pracy, Anne-Marie Avery, Ian Hodgetts and Stan Gauden, HDR Brachytherapy for Superficial Non-Melanoma Skin Cancers, Journal of Medical Imaging and Radiation Oncology, 57, 2, (212), (2013).
    Crossref
  • Murad Alam, Shivani Nanda, Bharat B. Mittal, Natalie A. Kim and Simon Yoo, The use of brachytherapy in the treatment of nonmelanoma skin cancer: A review, Journal of the American Academy of Dermatology, 65, 2, (377), (2011).
    Crossref
  • Vishal Madan, John T Lear and Rolf-Markus Szeimies, Non-melanoma skin cancer, The Lancet, 10.1016/S0140-6736(09)61196-X, 375, 9715, (673-685), (2010).
    Crossref
  • Shane E. Cotter, Phillip M. Devlin, Debjani Sahni, Jorgen L. Hansen, Desmond A. O'Farrell, Andrea K. Ng and Linda C. Wang, Treatment of Cutaneous Metastases of Merkel Cell Carcinoma With Surface-Mold Computer-Optimized High-Dose-Rate Brachytherapy, Journal of Clinical Oncology, 28, 27, (e464), (2010).
    Crossref